Early clinical promise for HCV antiviral combinations
This article was originally published in Scrip
Executive Summary
A combination of the nucleoside polymerase inhibitor RG7128 and the protease inhibitor RG7227 reduced viral load in a Phase I trial of hepatitis C virus patients, report InterMune, Pharmasset and Roche.